Evotec SE is a biopharmaceutical company that provides drug discovery and development services. The company operates through its scientific solutions and services, offering expertise in areas such as cell and gene therapy, oncology, and immunology. Evotec supports pharmaceutical and biotechnology clients by providing integrated research and development capabilities, including target identification, lead optimization, and preclinical development. The company serves customers in the global biopharmaceutical industry, facilitating the advancement of new therapeutic candidates from early discovery through to clinical stages. Evotec engages in partnerships with major life science firms to deliver customized scientific solutions.

Summarised from the company's own disclosures

Industry Biotechnology Homepage evotec.com
Sector Healthcare IR page evotec.com/ir-news
Tags
drug discovery, contract research, biopharmaceutical services, cell and gene therapy, oncology, immunology, preclinical development, target identification, Evotec
Press page —

Metrics

Valuation  
Market cap € 500.629M
Market cap (USD) $ 550.141M
P/E -2.79
PEG —
P/BV —
P/S 0.64
P/OCF -54.54
P/FCF —
Dividend yield —
Turnover / mcap —
Returns  
ROE —
ROI —
ROIC —
Profit margin -13.1%
Growth  
Revenue growing No
Profits growing No
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding No
Buying back stock No
Diluting (TTM) No
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 0
Quality score -69.2%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2018
Revenue 788.373M 796.967M 781.426M 751.448M 618.034M 500.924M 0
Net profit -103.517M -196.078M -83.913M -175.655M 215.51M 6.278M 0
Free cash flow -81.721M -99.248M -176.882M 21.752M 3.294M -54.351M —

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2018
Share price 2.62 3.79 10.78 8.03 20.15 — —
Price performance 12m -0.26 -0.65 0.45 -0.66 — — —

Filed figures

Figure Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Income detail
Research and development expense (EUR) 58.4M 63.9M 72.2M 76.6M 68.5M 50.9M 37.5M
↳ 5y CAGR -2.7% -10.1%
Reported Apr 26, 2022 Apr 26, 2022 Apr 26, 2022 May 12, 2023 Aug 14, 2024 Apr 17, 2025 Apr 8, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Release of a capital market information Bull 1 Bear 0 Capital return
Release of a capital market information Bull 2 Bear 0 Capital return

Prompts

Evotec SE (ticker EVT), listed in Germany.

ETFs Holding Evotec SE

ETF Weight in ETF Shares Market value As of
IDYN 0.13% 1,672 $ 144.572K Nov 16, 2026
CORO 0.09% 171,685 $ 14.846M Nov 16, 2026
DISV 0.01% 183,916 $ 635.828K Nov 12, 2026
LCTD 0.01% 437 $ 37.786K Nov 16, 2026
DFAX 0.00% 86,591 $ 299.36K Nov 12, 2026
DFIS 0.00% 19,075 $ 65.945K Nov 12, 2026
DFIC 0.00% 26,589 $ 91.923K Nov 12, 2026

Securities

Ticker Type Class Market Exchange Last price Price date
EVO Common share — US nasdaq 1.71 USD 2026-09-30
EVT canonical Common share — DE xetra 2.82 EUR 2026-10-30